ESTA — Establishment Labs Holdings Inc

Is ESTA overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Devices

Oversold As of August 19, 2026

Establishment Labs Holdings Inc (ESTA) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Medical Devices) last closed at $75.36. The rating moved from Neutral to Oversold on August 17, 2026.

See all oversold Healthcare stocks →

AI analysis

Establishment Labs is a differentiated player in aesthetic implantables with proprietary technology, premium pricing, and an entrenched global distribution footprint that supports above‑average margins. Near‑term upside drivers include continued recovery of elective procedures, international expansion, and incremental product rollouts; however, the business remains exposed to regulatory, litigation, and elective‑spend cyclicality that can cause sharp earnings variability. Maintain focus on upcoming operational disclosures, any safety/regulatory updates, and quarterly trends in procedure volumes as primary near‑term catalysts or warning signs.

Key factors

  • Market position: recognized niche leader in aesthetic breast implants and related implantable devices with an established global distribution network
  • Product portfolio: differentiated product features (e.g., Motiva platform) and ongoing incremental product launches that support ASP stability and premium positioning
  • Revenue and margin profile: historically higher gross margins vs commodity implant competitors due to proprietary technology and vertical integration in manufacturing
  • Growth runway: expanding international penetration, elective-procedure recovery tailwinds, and potential adjacencies (services, data/clinic solutions) that can drive mid‑cycle revenue growth
  • Regulatory / quality track record: relatively clean recent regulatory history compared with high‑profile implant recalls, supporting surgeon and patient confidence
  • Macro/sector readthroughs: selective interest in growth/medical-device names in the current market and steady short‑term risk appetite among participants

Risks

  • Regulatory and product‑liability risk: implants are subject to heightened safety scrutiny and recalls or litigation could materially damage sales and margins
  • Elective‑procedure cyclicality: demand for cosmetic procedures is sensitive to macro conditions and consumer discretionary spending shifts
  • Competition and pricing pressure: larger incumbents and new entrants may pressure share and mix, especially in price-sensitive markets
  • Supply‑chain or manufacturing disruption: concentrated manufacturing for implantable devices could cause shipment delays or increased costs
  • Currency and international exposure: a meaningful portion of sales comes from outside the U.S., introducing FX and geopolitical execution risk
  • Limited public information window: lack of fresh filings or social/research data in the provided window increases near‑term information risk

See today's live rating, score and targets

Members see the live hourly rating for ESTA — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.